Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18820993 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | August 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18832297 | PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6-CONTAINING MULTI- COMPONENT MATERIAL | July 2024 | April 2025 | Allow | 9 | 1 | 0 | No | No |
| 18832315 | PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6 COMPRISING FISHING NETS | July 2024 | April 2025 | Allow | 9 | 1 | 0 | No | No |
| 18645972 | CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALT | April 2024 | July 2024 | Allow | 3 | 1 | 0 | No | No |
| 18611685 | 8-((4-HYDROXY-3-METHOXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18584672 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | February 2024 | February 2025 | Allow | 12 | 1 | 0 | No | No |
| 18584177 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18391693 | REDOX ACTIVE MATERIALS, PROCESSES AND USES THEREOF | December 2023 | February 2025 | Allow | 14 | 1 | 0 | No | No |
| 18542913 | CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3, 4-TETRAHYDROCYCLO-PENTA [B]INDOL-3-YL)ACETIC ACID(COMPOUND1) FOR USE IN SIPI RECEPTOR-ASSOCIATED DISORDERS | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18533894 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | December 2023 | April 2024 | Allow | 4 | 2 | 0 | No | No |
| 18514959 | INHIBITORS OF LRRK2 KINASE | November 2023 | June 2025 | Allow | 18 | 2 | 0 | No | No |
| 18513229 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | November 2023 | March 2025 | Allow | 15 | 1 | 1 | No | No |
| 18389574 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LOWE SYNDROME | November 2023 | January 2025 | Allow | 15 | 2 | 0 | No | No |
| 18507013 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | November 2023 | April 2025 | Allow | 18 | 1 | 0 | No | No |
| 18385808 | 8-((4-HYDROXY-3-METHYLPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18385586 | 8-(4-nitroxybenzylideneamino)naphthalene-1,3-disulfonic acid AS AN ANTIOXIDANT COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18495845 | Oral Formulation of Clonidine and Midazolam for Sedation in Dental Procedures | October 2023 | July 2024 | Allow | 9 | 0 | 0 | No | No |
| 18382896 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | October 2023 | May 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18486759 | ANTI-VIRAL COMPOUNDS | October 2023 | October 2024 | Allow | 12 | 1 | 0 | No | No |
| 18243771 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18463407 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | September 2023 | October 2024 | Allow | 14 | 1 | 0 | No | No |
| 18462488 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | September 2023 | January 2025 | Allow | 16 | 2 | 0 | No | No |
| 18448497 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | August 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18363933 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | August 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18225589 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | July 2023 | February 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18328865 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | June 2023 | January 2025 | Allow | 20 | 1 | 0 | No | No |
| 18255969 | SYNTHESIS OF STRUCTURAL ANALOGS OF LARGAZOLE AND ASSOCIATED COMPOUNDS | June 2023 | October 2024 | Allow | 16 | 2 | 0 | No | No |
| 18323510 | Heterocyclic Adenosine Receptor Antagonists | May 2023 | November 2024 | Allow | 18 | 2 | 0 | No | No |
| 18196459 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | May 2023 | February 2025 | Allow | 21 | 1 | 0 | No | No |
| 18140348 | BENZAZEPINE DERIVATIVES | April 2023 | March 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18307181 | RIP1K INHIBITORS | April 2023 | January 2025 | Allow | 21 | 2 | 0 | No | No |
| 18135898 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | April 2023 | January 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18135499 | MEDICAMENT FOR TREATING COUGH | April 2023 | November 2024 | Allow | 19 | 1 | 1 | No | No |
| 18301742 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | April 2023 | October 2023 | Allow | 6 | 1 | 0 | No | No |
| 18300350 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | April 2023 | April 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18128603 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | March 2023 | April 2025 | Allow | 24 | 2 | 1 | No | No |
| 18126953 | COMPOSITIONS AND METHODS FOR TREATING RHEUMATOID ARTHRITIS | March 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18180997 | PROCESS FOR PREPARING LEVOKETOCONAZOLE | March 2023 | June 2023 | Allow | 3 | 1 | 0 | No | No |
| 18119321 | METHODS OF TREATMENT | March 2023 | August 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18164974 | Antiviral Pyrazolopiridinone Compounds | February 2023 | February 2025 | Allow | 24 | 1 | 0 | No | No |
| 18162432 | PROCESS FOR THE PREPARATION OF DRUG LINKER COMPOUNDS | January 2023 | January 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18095621 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | January 2023 | January 2024 | Allow | 13 | 2 | 0 | No | No |
| 18087338 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | December 2022 | August 2024 | Allow | 20 | 1 | 0 | No | No |
| 18086076 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | December 2022 | June 2025 | Allow | 30 | 2 | 0 | No | No |
| 18078511 | Charged Ion Channel Blockers and Methods for Use | December 2022 | November 2024 | Abandon | 23 | 1 | 0 | No | No |
| 18073897 | METHODS OF TREATING PATIENTS SUFFERING FROM BRAIN INJURY AND METHODS OF INCREASING THE VALUE OF THE EXTENDED GLASGOW OUTCOME SCALE OF PATIENTS SUFFERING FROM BRAIN INJURY | December 2022 | August 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 18059838 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | November 2022 | November 2024 | Allow | 23 | 1 | 1 | No | No |
| 17991899 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | November 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 17992371 | Antifibrotic Compounds And Related Methods | November 2022 | July 2024 | Allow | 20 | 1 | 0 | No | No |
| 17989237 | 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV | November 2022 | February 2024 | Allow | 15 | 0 | 0 | No | No |
| 17988366 | Aceclidine Derivatives, Compositions Thereof and Methods of Use Thereof | November 2022 | August 2024 | Allow | 21 | 3 | 0 | No | No |
| 17978696 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | November 2022 | December 2024 | Allow | 25 | 2 | 0 | No | No |
| 17977371 | PHARMACEUTICAL COMPOSITIONS AND METHODS | October 2022 | May 2024 | Allow | 19 | 1 | 0 | No | No |
| 17975623 | APPLICATION OF ANLE138B IN DRUG FOR IMPROVING DIET-INDUCED INSULIN RESISTANCE | October 2022 | March 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17971865 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | October 2022 | November 2023 | Allow | 12 | 0 | 0 | No | No |
| 17967301 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | October 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 17967308 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | October 2022 | May 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 17918607 | Synthesis of Vinylic Protected Alcohol Intermediates | October 2022 | June 2025 | Allow | 32 | 1 | 0 | No | No |
| 17937740 | NON-SURGICAL PREVENTION OF BOAR TAINT AND AGGRESSIVE BEHAVIOR | October 2022 | December 2023 | Allow | 23 | 2 | 0 | No | No |
| 17934069 | Fixed Dose Oral Testosterone Undecanoate Compositions and Use Thereof | September 2022 | March 2024 | Allow | 18 | 1 | 0 | No | No |
| 17948684 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | September 2022 | May 2024 | Allow | 20 | 1 | 0 | No | No |
| 17946112 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | September 2022 | February 2023 | Allow | 5 | 1 | 0 | No | No |
| 17946024 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | September 2022 | February 2023 | Allow | 5 | 1 | 0 | No | No |
| 17942120 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | September 2022 | February 2023 | Allow | 5 | 1 | 0 | No | No |
| 17942121 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | September 2022 | February 2023 | Allow | 6 | 1 | 0 | No | No |
| 17942112 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | September 2022 | February 2023 | Allow | 5 | 1 | 0 | No | No |
| 17942123 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | September 2022 | March 2023 | Allow | 6 | 1 | 0 | No | No |
| 17942122 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | September 2022 | February 2023 | Allow | 5 | 1 | 0 | No | No |
| 17942111 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | September 2022 | February 2023 | Allow | 5 | 1 | 0 | No | No |
| 17942106 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | September 2022 | February 2023 | Allow | 5 | 1 | 0 | No | No |
| 17930352 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | September 2022 | July 2024 | Allow | 23 | 1 | 1 | No | No |
| 17939020 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | September 2022 | June 2024 | Allow | 21 | 2 | 0 | No | No |
| 17905626 | L-ERGOTHIONEINE-CONTAINING COMPOSITION | September 2022 | May 2025 | Allow | 33 | 0 | 0 | No | No |
| 17902085 | BIASED ADRENERGIC AGONISTS | September 2022 | January 2024 | Allow | 16 | 3 | 1 | No | No |
| 17905327 | PROCESS FOR THE PURIFICATION OF INDOLE CARBAZOLE ALKALOIDS | August 2022 | May 2025 | Allow | 33 | 2 | 0 | No | No |
| 17799680 | METHODS OF PREPARING CHIRAL BENZODIAZEPINONE DERIVATIVES | August 2022 | April 2025 | Allow | 32 | 1 | 0 | No | No |
| 17819178 | ANTIVIRAL DRUGS TARGETING THE N-TERMINAL DOMAIN (NTD) OF THE CORONAVIRUS SPIKE RECEPTOR BINDING DOMAIN (RBD) | August 2022 | August 2023 | Allow | 12 | 1 | 0 | No | No |
| 17882707 | CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND THEIR USES | August 2022 | February 2024 | Allow | 18 | 1 | 0 | No | No |
| 17873246 | Self-Healing Organic Crystals | July 2022 | September 2023 | Allow | 13 | 1 | 0 | No | No |
| 17874122 | Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate | July 2022 | February 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17811201 | RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION | July 2022 | December 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17811008 | ANTI-VIRAL COMPOUNDS | July 2022 | September 2023 | Allow | 15 | 2 | 0 | No | No |
| 17853497 | 5 BETA DIHYDROTESTOSTERONE PHARMACEUTICAL FORMULATIONS AND RELATED METHODS | June 2022 | March 2024 | Allow | 20 | 2 | 0 | No | No |
| 17850144 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | June 2022 | December 2024 | Allow | 30 | 3 | 0 | No | No |
| 17787369 | METHOD FOR PREPARING LURASIDONE HYDROCHLORIDE | June 2022 | January 2025 | Allow | 31 | 0 | 0 | No | No |
| 17786470 | 1,4-Sulfur-Bridged Polycyclic Compounds Containing Dihydrobenzofuran Structure, Its Preparation Method and Application Thereof | June 2022 | July 2024 | Allow | 25 | 1 | 0 | No | No |
| 17836070 | ADENINE ANALOGS, PRODRUGS, DERIVATIVES, COMPOSITIONS AND USES THEREOF | June 2022 | August 2024 | Abandon | 26 | 3 | 1 | Yes | No |
| 17833160 | TRIDENTATE MACROCYCLIC COMPOUNDS | June 2022 | July 2023 | Allow | 13 | 1 | 0 | No | No |
| 17804979 | ALBOFUNGIN AND ITS DERIVATIVES SPECIFICALLY RECOGNIZE HIV-1 LTR-III G-QUADRUPLEX | June 2022 | July 2023 | Allow | 13 | 1 | 0 | No | No |
| 17751613 | CLOMIPRAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | May 2022 | December 2023 | Allow | 18 | 2 | 0 | No | No |
| 17777739 | METHOD FOR PRODUCING EPSILON-CAPROLACTAM | May 2022 | March 2025 | Allow | 34 | 1 | 0 | No | No |
| 17744429 | CRYSTAL MODIFICATIONS OF ODEVIXIBAT | May 2022 | July 2024 | Allow | 26 | 2 | 0 | No | No |
| 17773607 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | April 2022 | February 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17726153 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | April 2022 | November 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17724753 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | April 2022 | April 2025 | Allow | 36 | 4 | 0 | Yes | No |
| 17722947 | MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE | April 2022 | February 2024 | Allow | 22 | 1 | 0 | No | No |
| 17766496 | REDOX ACTIVE MATERIALS, PROCESSES AND USES THEREOF | April 2022 | August 2023 | Allow | 16 | 2 | 0 | No | No |
| 17706225 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | March 2022 | July 2024 | Allow | 28 | 2 | 0 | No | No |
| 17695033 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | March 2022 | October 2022 | Allow | 7 | 1 | 0 | No | No |
| 17694896 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | March 2022 | January 2023 | Abandon | 10 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COLEMAN, BRENDA LIBBY.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 37.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner COLEMAN, BRENDA LIBBY works in Art Unit 1624 and has examined 2,092 patent applications in our dataset. With an allowance rate of 73.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.
Examiner COLEMAN, BRENDA LIBBY's allowance rate of 73.3% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by COLEMAN, BRENDA LIBBY receive 1.58 office actions before reaching final disposition. This places the examiner in the 41% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by COLEMAN, BRENDA LIBBY is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +15.5% benefit to allowance rate for applications examined by COLEMAN, BRENDA LIBBY. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 38.0% of applications are subsequently allowed. This success rate is in the 84% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 64.7% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 90.7% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 85.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 54.6% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 6.7% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.1% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.